Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/Pathologymedical mutual - ohio vitamin B12 MMA Coverage Upd…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy AHS - G2014

    Vitamin B12 and Methylmalonic Acid Testing

    Customize your policy alerts

    Sign up for medical mutual - ohio Policy AHS - G2014 alerts

    Get alerted when Policy AHS - G2014 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage criteria for serum vitamin B12 (total cobalamin), methylmalonic acid (MMA), and related laboratory tests for diagnosing and monitoring vitamin B12 deficiency; governs medical mutual - ohio members and providers ordering these tests.

    Policy Summary
    Payermedical mutual - ohio
    PolicyVitamin B12 and Methylmalonic Acid Testing
    Policy CodePolicy AHS - G2014
    Change TypeMinor — no material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionOrder serum vitamin B12 only when clinical signs, risk factors, or treatment monitoring criteria are documented; allow total B12 testing once every three months when criteria are met.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    q3 monthsfrequency allowed for total vitamin B12 testing in covered situations
    MMA recommendedMMA coverage stance
    not coveredholotranscobalamin coverage
    not coveredhomocysteine coverage
    4procedure codes listed
    12/03/2025last review date

    Coverage Criteria for Vitamin B12 and MMA Testing

    Total vitamin B12 testing (serum cobalamin)

    Covered when ANY of the following are met; testing allowed once every three months:

    Covered indications: 1) Presence of signs or symptoms of vitamin B12 deficiency (cutaneous: hyperpigmentation, jaundice, vitiligo; gastrointestinal: glossitis; hematologic: anemia [macrocytic/megaloblastic], leukopenia, pancytopenia, thrombocytopenia, thrombocytosis; neuropsychiatric: areflexia, cognitive impairment including dementia-like symptoms and acute psychosis, gait abnormalities, irritability, loss of proprioception and vibratory sense, olfactory impairment, peripheral neuropathy).once every 3 months

    From policy coverage section.

    Covered indications: 2) Individuals undergoing treatment for vitamin B12 deficiency.once every 3 months

    From policy coverage section.

    Covered indications: 3) Individuals with one or more risk factors for vitamin B12 deficiency, including: decreased ileal absorption (Crohn disease, ileal resection, tapeworm infection, prior or planned bariatric procedures such as Roux-en-Y gastric bypass, sleeve gastrectomy, biliopancreatic diversion/duodenal switch); decreased intrinsic factor (atrophic gastritis, pernicious anemia, postgastrectomy syndrome); genetic (transcobalamin II deficiency); inadequate intake (alcohol abuse, age >75 or elderly evaluated for dementia, vegans/strict vegetarians including exclusively breastfed infants of vegetarian/vegan mothers, eating disorder); prolonged medication use (H2 blockers >12 months, metformin >4 months, proton pump inhibitors >12 months).once every 3 months

    From policy coverage section.

    Methylmalonic acid (MMA) testing

    Covered when ANY of the following are met:

    Covered indications: 1) Asymptomatic high‑risk individuals with low‑normal serum vitamin B12, or when B12 deficiency is suspected but total serum B12 is normal or low‑normal — methylmalonic acid (MMA) testing to confirm deficiency.not specified

    Policy: MMA meets coverage criteria in these scenarios (confirmation).

    Covered indications: 2) Evaluation of inborn errors of metabolism — MMA testing meets coverage criteria.not specified

    Policy: MMA indicated for metabolic/inborn errors.

    Covered indications: 3) When initial plasma/serum B12 is indeterminate and clinical suspicion persists (consensus guidance supports measurement of a metabolic marker such as MMA to guide diagnosis and to monitor treatment effectiveness).not specified

    Not covered tests or uses

    The following are explicitly not covered:

    Not covered: 1) Screening of healthy, asymptomatic individuals for vitamin B12 deficiency (does not meet coverage criteria).

    Explicit statement in policy.

    Not covered: 2) Homocysteine testing for confirmation of vitamin B12 deficiency (does not meet coverage criteria).

    Explicit statement in policy.

    Not covered: 3) Holotranscobalamin testing for screening, testing, or confirmation of vitamin B12 deficiency (does not meet coverage criteria).

    Explicit statement in policy and not covered list.

    Not covered: 4) Total vitamin B12 testing for situations not described in the covered indications above (does not meet coverage criteria).

    Covered indications per guideline consensus

    Covered when testing is supported by guideline‑recommended indications or risk factors

    Suspected clinical deficiency: Order CBC and serum vitamin B12 for patients presenting with relevant clinical manifestations (cutaneous, gastrointestinal, hematologic, neuropsychiatric) or abnormal blood counts such as macrocytosis.

    AAFP and guideline recommendations: CBC + serum B12 as initial evaluation.

    Patients with risk factors: Testing is appropriate in patients with recognized risk factors (e.g., malabsorption, pernicious anemia, post‑gastrectomy or bariatric surgery, elderly >75, vegans/strict vegetarians, prolonged H2 blocker/PPI or metformin use).

    AAFP, ASMBS and related societies list specific risk factors warranting testing.

    Bariatric surgery patients: Preoperative and routine postoperative B12 screening is recommended for patients undergoing RYGB, SG, BPD/DS; consider MMA (with or without homocysteine) to identify metabolic deficiency.post-op: more frequent checks q3 months first year then at least annually

    Medically supported indications

    Testing is supported when clinical presentation and/or risk factors align with professional guidance:

    Supported indications: Testing for vitamin B12 (serum B12) or metabolic markers (MMA or homocysteine) is appropriate when: (1) patients have symptoms/signs consistent with B12 deficiency (eg, anemia, macrocytosis, neuropathy, cognitive changes, unexplained fatigue), OR (2) patients have recognized risk factors (eg, restrictive diets, malabsorption conditions, chronic metformin use, bariatric surgery, certain medications), OR (3) monitoring is needed for treatment effectiveness when metabolic markers such as MMA are available per Consensus Panel recommendations.

    Derived from ADA, NICE, Consensus Panel, BMJ guidance in document.

    Reflex / second-tier testing

    Reflex or second‑tier testing logic:

    Cascade testing: If initial plasma/serum B12 is indeterminate or the clinical picture is uncertain, measure a metabolic marker (plasma MMA; or total homocysteine if MMA unavailable) to guide diagnosis. MMA can also be used to monitor treatment effectiveness, particularly for oral therapy or when absorption is in question.

    Consensus Panel and NICE guidance support cascade/reflex testing.

    Screening of healthy, asymptomatic individuals for vitamin B12 deficiency is explicitly excluded from coverage and does not meet coverage criteria per the policy.

    Routine screening of asymptomatic, average‑risk individuals is not supported by the evidence and is not routinely indicated; the policy and the Doctors of BC guidance both discourage routine B12 testing in patients without symptoms or risk factors.

    The BMJ notes that serum biomarkers, including serum B12 and MMA, are unreliable predictors of B12‑responsive neuropathy and that measuring these biomarkers is neither helpful nor indicated to assess or monitor clinical improvement; clinical monitoring of symptoms should guide treatment decisions.

    The policy states that homocysteine testing for confirmation of vitamin B12 deficiency and holotranscobalamin testing for screening, testing, or confirmation do not meet coverage criteria and are considered not covered under this policy.

    Using vitamin B12 supplementation or testing solely as a strategy to prevent cardiovascular disease is not supported by the evidence; studies show B‑vitamin supplementation lowers homocysteine but does not reduce cardiovascular events, and the policy therefore does not support B12 testing for CVD prevention alone.

    Indications That Meet Coverage

    Diagnosis or monitoring of vitamin B12 deficiency

    Diagnosis or monitoring of vitamin B12 deficiency when signs/symptoms, risk factors, or treatment monitoring present as listed; MMA for confirmation in low‑normal cases and for inborn errors of metabolism.

    Covered indications: 1) Diagnosis of suspected vitamin B12 deficiency in patients with clinical manifestations (cutaneous, gastrointestinal, hematologic, neuropsychiatric) or laboratory abnormalities (eg, macrocytosis, anemia).

    Initial evaluation: CBC + serum B12; proceed to MMA if indeterminate and suspicion persists (AAFP).

    Covered indications: 2) Monitoring patients undergoing treatment for vitamin B12 deficiency — when clinical management or monitoring requires biochemical assessment; consider MMA for monitoring treatment effectiveness per Consensus Panel guidance.

    Policy allows total B12 testing during treatment; MMA useful to monitor response.

    Covered indications: 3) Use MMA to confirm deficiency in patients with low‑normal serum B12 or when B12 deficiency is suspected despite a normal/low‑normal total serum B12; MMA meets coverage criteria for inborn errors of metabolism as well.

    Testing Frequency and Monitoring Intervals

    inv-41: Total vitamin B12 (serum cobalamin) — once every 3 months.
    TestTotal vitamin B12 (serum cobalamin)
    Frequency limitOnce every 3 months when coverage criteria are met
    Covered usesDiagnosis or monitoring of B12 deficiency for patients with compatible signs/symptoms, risk factors, or undergoing treatment
    DocumentationOrder must be supported by clinical indications or risk factors per policy
    inv-42: Serum B12 (MMA optional/adjunct per guidance) — More frequent (e.g., every 3 months) in first postoperative year, then at least annually; consider q36 months if supplemented per some sources.
    TestSerum vitamin B12 (with MMA optional/adjunct)

    Provider Actions, Documentation, and Operational Rules

    Documentation Required

    Pre-treatment sample collection

    Pre-treatment sample collection: For cases of suspected remethylation disorders or when total homocysteine is markedly elevated, document that plasma and urine samples for determination of methylmalonic acid (MMA), methionine, folate, and vitamin B12 were obtained before initiating treatment. This is required to ensure accurate biochemical assessment and appropriate interpretation of results.

    • Obtain and document plasma and urine samples for MMA, methionine, folate, and vitamin B12 prior to starting therapy in suspected remethylation disorders or when total homocysteine is high.
    • Failure to document pre-treatment collection may lead to denial or requests for additional information.
    Note

    Provider actions — Not specified / Documentation requirements

    Not specified: General provider actions — The policy does not require a separate prior authorization process for the listed laboratory tests; however, providers must document clinical indications (signs/symptoms, risk factors, or treatment monitoring) that meet coverage criteria. Routine screening in asymptomatic individuals without risk factors does not meet coverage criteria and may be denied. Requests for homocysteine or holotranscobalamin to confirm B12 deficiency are not covered and will be denied.

    Applicable Procedure Codes

    Applicable CPT/HCPCS Procedure CodesCPT
    82607Cyanocobalamin (Vitamin B-12).
    83090Homocysteine.
    83921Organic acid, single, quantitative.
    84999Unlisted chemistry procedure

    Ordering Requirements and Who May Order

    Documentation Required

    Order must be supported by listed clinical indications or risk factors

    Orders for B12 or MMA testing must be supported in the chart by the clinical indications or risk factors listed in the policy (signs/symptoms, treatment monitoring, or listed risk factors).

    • Policy ordering requirement: orders must be supported by covered indications (III sections).
    Note

    No explicit restriction on who may order testing

    The policy does not restrict who may order these tests; standard clinical practice implies that the clinician responsible for the patient's care (primary care or relevant specialist) should place the order.

    • AAFP recommended evaluation and no provider‑type ordering restriction stated in policy; order per clinician managing the patient.
    Documentation Required

    Order tests per clinical context and cited guidelines

    Services and Uses Not Covered

    The following tests and uses are not covered: holotranscobalamin testing for screening, testing, or confirmation; homocysteine testing for confirmation of vitamin B12 deficiency; and screening in healthy, asymptomatic patients.

    Routine vitamin B12 screening in asymptomatic, average‑risk individuals is not supported by evidence and is therefore not covered; likewise, the use of B12 testing as a cardiovascular disease prevention strategy is not supported.

    The policy does not support using serum biomarkers (serum B12 or MMA) alone to assess or monitor clinical improvement in neuropathy. The BMJ advises basing treatment frequency and clinical decisions on symptoms rather than biomarker normalization.

    Definitions and Test Descriptions

    inv-29: Methylmalonic acid (MMA) — A metabolite that accumulates when vitamin B12 is unavailable and is used as an indicator of functional B12 deficiency.
    DefinitionMethylmalonic acid (MMA) is a metabolite that accumulates when vitamin B12 is unavailable
    Clinical roleUsed as an indicator of functional B12 deficiency and to confirm suspected deficiency when serum B12 is indeterminate
    Analytical noteElevated MMA has high sensitivity (>95%) for overt cobalamin deficiency; specificity varies by context
    Use casesUseful for newborn screening algorithms and as an adjunct diagnostic marker
    inv-30: Holotranscobalamin (holoTC) — The metabolically active fraction of vitamin B12 and an emerging marker of impaired B12 status; not clinically validated for widespread use.
    Definition

    Background and Evidence Context

    Vitamin B12 (cobalamin) is essential for hematologic, neurologic, and DNA synthesis functions; deficiency can produce hematologic abnormalities and neuropsychiatric or neurologic manifestations that may be reversible if identified and treated early. Methylmalonic acid (MMA) accumulates when B12 is unavailable and serves as an indicator of functional B12 deficiency, while holotranscobalamin represents the metabolically active fraction but is not covered for routine clinical use in this policy.

    Revision History

    2025-12-03reviewLatest

    Reviewed and updated background, guidelines, recommendations, and evidence references; literature review did not require changes to coverage criteria.

    Policy Summary
    Payermedical mutual - ohio
    PolicyVitamin B12 and Methylmalonic Acid Testing
    Policy CodePolicy AHS - G2014
    Change TypeMinor — no material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionOrder serum vitamin B12 only when clinical signs, risk factors, or treatment monitoring criteria are documented; allow total B12 testing once every three months when criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Vitamin B12 and MMA TestingIndications That Meet CoverageTesting Frequency and Monitoring IntervalsProvider Actions, Documentation, and Operational RulesApplicable Procedure CodesOrdering Requirements and Who May OrderServices and Uses Not CoveredDefinitions and Test DescriptionsBackground and Evidence ContextRevision History

    Consensus Panel and guideline recommendations.

    Policy limitation.

    ASMBS, BOMSS and other societies recommend baseline and ongoing surveillance.

    Metformin users: Periodic assessment of vitamin B12 levels should be considered in patients on chronic metformin therapy, particularly if neuropathy or unexplained anemia is present.annual consideration per consensus

    ADA and Consensus Panel recommendations.

    High homocysteine/remethylation disorders: In cases of high total homocysteine or suspected remethylation disorders, obtain plasma and urine MMA, methionine, folate and B12 samples before starting treatment.

    E‑HOD international consortium recommendation.

    Policy explicit statements.

    Suspected vitamin B12 deficiency based on clinical manifestations

    Suspected vitamin B12 deficiency based on clinical manifestations or laboratory findings:

    Clinical manifestations: Patients presenting with cutaneous (hyperpigmentation, jaundice, vitiligo), gastrointestinal (glossitis), hematologic (macrocytic/megaloblastic anemia, leukopenia, pancytopenia, thrombocytopenia, thrombocytosis), or neuropsychiatric findings (areflexia, cognitive impairment including dementia‑like symptoms and acute psychosis, gait abnormalities, irritability, loss of proprioception and vibratory sense, olfactory impairment, peripheral neuropathy).

    AAFP listed manifestations.

    Laboratory findings: Patients with abnormal CBC results such as macrocytosis or anemia warrant serum B12 testing as part of initial evaluation; if serum B12 is normal/low‑normal but suspicion persists, obtain MMA.

    AAFP stepwise testing recommendation.

    Preoperative and postoperative monitoring for bariatric surgery patients (RYGB, SG, BPD/DS)

    Preoperative and postoperative monitoring for bariatric surgery patients (RYGB, SG, BPD/DS):

    Bariatric pre/postoperative testing: Baseline vitamin B12 assessment is recommended preoperatively; routine postoperative screening for patients undergoing RYGB, SG, or BPD/DS is recommended. More frequent screening (eg, every 3 months) is recommended in the first postoperative year, then at least annually thereafter; consider MMA (with or without homocysteine) to identify metabolic deficiency in symptomatic or high‑risk patients.post-op: q3 months first year then at least annually

    ASMBS and BOMSS guidance.

    Chronic metformin therapy and patients with diabetes with neuropathy or unexplained anemia

    Chronic metformin therapy and patients with diabetes with neuropathy or unexplained anemia:

    Metformin-associated monitoring: Consider periodic assessment of vitamin B12 levels in patients on long‑term metformin therapy; measure B12 annually in chronic metformin users or when neuropathy or unexplained anemia is present.once per year (consensus recommendation)

    ADA and Consensus Panel recommendations.

    High total homocysteine or suspected remethylation disorders

    High total homocysteine or suspected remethylation disorders — pre‑treatment sample collection:

    Pre-treatment testing: In cases of high total homocysteine or suspected remethylation disorders, obtain plasma and urine samples for determination of MMA, methionine, folate and vitamin B12 before starting treatment.

    E‑HOD international consortium recommendation (Guidelines for Cobalamin‑related Remethylation Disorders).

    Suspected vitamin B12 deficiency based on symptoms or risk factors

    Suspected vitamin B12 deficiency based on symptoms or risk factors (dietary restrictions, malabsorption, chronic metformin use, medications, history of bariatric surgery):

    Symptoms or risk factors: Testing is supported when patients present with suggestive symptoms (eg, anemia, macrocytosis, neuropathy, cognitive impairment, unexplained fatigue) or have risk factors such as restrictive diets (vegans/strict vegetarians), malabsorption (Crohn disease, ileal resection), chronic metformin use, prolonged H2 blocker or PPI use, certain medications, or history of bariatric surgery.

    NICE, AAFP, ADA and other societies support testing when symptom(s) plus risk factor(s) are present.

    Monitoring and surveillance: Consensus Panel recommends annual assessment for chronic metformin users; NICE recommends testing when a common symptom plus a common risk factor are present; ADA recommends considering B12 measurement in patients with diabetes and neuropathy or unexplained anemia.annual for chronic metformin users

    Guideline-driven frequency guidance.

    Frequency guidanceMore frequent (e.g., every 3 months) in the first postoperative year after bariatric surgery, then at least annually; consider every 36 months if adequately supplemented per some societies
    Use caseConsider MMA (with or without homocysteine) to identify metabolic deficiency when serum B12 may be inadequate
    PopulationApplied to preoperative and postoperative bariatric patients and those on medications that increase deficiency risk
    inv-43: Plasma B12 assessment for patients on chronic metformin — Once per year recommended by Consensus Panel.
    TestPlasma B12 (B12 status assessment) for chronic metformin users
    RecommendationMeasure B12 status once per year for patients on chronic metformin to detect deficiency before clinical manifestation
    ContextParticularly relevant for patients with diabetes who have neuropathy or unexplained anemia
    SourceConsensus Panel and ADA recommendations
    • Document clinical signs/symptoms and/or risk factors when ordering B12 or MMA testing (cutaneous, gastrointestinal, hematologic, neurologic, medication history, bariatric surgery, age >75, dietary factors, etc.).
    • Requests for vitamin B12 testing for healthy, asymptomatic individuals for screening will be denied.
    • Requests for homocysteine testing to confirm vitamin B12 deficiency will be denied.
    • Requests for holotranscobalamin testing for screening, testing, or confirmation of vitamin B12 deficiency will be denied.
    • No explicit prior authorization requirement is specified in this policy; follow applicable payer or government program rules if present.

    Order tests consistent with guideline recommendations: NICE recommends targeted testing based on symptoms plus risk factors; Consensus Panel and ADA provide context‑specific recommendations (e.g., annual testing for chronic metformin users).

    • NICE: test when a common symptom plus a common risk factor are present.
    • Consensus Panel/ADA: guidance on metabolic marker use and periodic assessment for metformin users.
    Holotranscobalamin (holoTC) is the metabolically active fraction of vitamin B12
    Clinical statusEmerging marker of impaired B12 status but not yet clinically validated for widespread use
    Analytical noteMay have slightly better sensitivity than total serum cobalamin, but specificity and availability are limited
    inv-31: Serum cobalamin — First-line biochemical test to assess vitamin B12 status; may be insufficient alone to identify functional deficiency.
    DefinitionSerum cobalamin (total B12) is the first-line biochemical test to assess vitamin B12 status
    LimitationMay be insufficient alone to identify functional deficiency; consider second-line markers when results are indeterminate
    Clinical useInitial evaluation with CBC and serum B12 recommended for patients with compatible signs/symptoms or risk factors
    inv-32: Plasma methylmalonic acid (MMA) — A second-line, more specific marker of functional vitamin B12 deficiency; helpful when serum B12 is indeterminate.
    DefinitionPlasma methylmalonic acid (MMA) is a second-line, more specific marker of functional vitamin B12 deficiency
    IndicationHelpful when serum B12 is indeterminate or low-normal but clinical suspicion persists
    MonitoringConsensus Panel recommends MMA can be used to monitor effectiveness of B12 treatment, including oral therapy
    inv-33: Methylmalonic acid (MMA) — Recommended by Consensus Panelists as useful to guide diagnosis and monitor treatment effect.
    DefinitionMethylmalonic acid (MMA) is a metabolic marker recommended by Consensus Panelists to guide diagnosis and monitor treatment effect
    UtilityUseful when clinical picture is uncertain and for monitoring treatment success, especially oral B12 therapy
    RecommendationPlasma MMA (or total homocysteine if MMA unavailable) should be made available for people suspected of B12 deficiency
    inv-34: Total B12 / Active B12 — Total B12 (serum cobalamin) or active B12 (holotranscobalamin): recommended by NICE as initial tests for suspected vitamin B12 deficiency.
    DefinitionTotal B12 (serum cobalamin) or active B12 (holotranscobalamin) recommended by NICE as initial tests for suspected vitamin B12 deficiency
    Testing approachNICE advises targeted testing when a common symptom plus a common risk factor are present; clinical judgment if symptoms alone
    Role of holoTCHolotranscobalamin is acknowledged as an active B12 marker but availability and validation limit widespread use